Immunogenic shiga-like toxin II variant mutants

Details Immunogenic shiga-like toxin II variant mutants Immunogenic shiga-like toxin II variant mutants

1994-01-10

1996-09-03

Walsh, Stephen G.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

4242411, 530350, 530825, 435200, A61K 39108, C07K 1425, C07K 14245, C12N 924

Patent

active

055521444

ABSTRACT:
Disclosed herein are immunogenic mutant Shiga-Like Toxin II variants and vaccines containing such toxins. The mutant toxin comprises an SLT-IIv where the amino acid at position 167 in the A subunit has been replaced by a differently charged amino acid that essentially maintains the structure of the native A subunit. In a preferred embodiment, the glutamic acid is replaced with glutamine. An analogous modification may also be made at position 170. The vaccines are used for edema disease of swine.

REFERENCES:
patent: 4136181 (1979-01-01), Dobrescu et al.
patent: 4632830 (1986-12-01), Formal et al.
patent: 4950740 (1990-08-01), Greenfield et al.
Yamasaki et al, "Analysis of Structure-Function Relationship of Vero Toxin (VTI) . . . ", Japan J. Med. Sci Biol. 42:180 (Oct.-Dec. 1989).
Head et al "Serological Differences Between Verocytotoxin 2 And Shiga-Like Toxin II", The Lancet (II):751 (Sep. 1988).
"Schulz et al, Principles of Protein Structure", pp. 14-16, Springer-Verlag (NY) 1979.
Gyles et al, "Cloning and Nucleotide sequence analysis of the genes determining verocytotoxin . . . " Microb. Pathog. 5:419-426 (1988).
Jackson et al, "Mutational Analysis of the Shiga Toxin . . ." J. Bacter. 172(6): 3346-3350 (Jun. 1990).
Yamasaki et al, "Importance of arginine at position 170 . . . " Microb. Pathog. 11(1): 1-9, abstract only (Jul. 1991).
Gyles et al, "Cloning and nucleotide sequence analysis . . . ", Chem. Abst. 110:181, Abst#186,883h (Feb. 1989).
Frankel et al, "Selection and Characterization of Ricin Toxin A-Chain . . . " Mol. Cell. Biol. 9(2); 415-420 (Feb. 1989).
Weinstein et al, "Cloning and Sequencing of a Shiga-Like Toxin Type II . . . " J. Bacter. 170(9): 4223-4230 (Sep. 1988).
Hovde et al, "Evidence that glutanic acid 167 is an active site residue . . . " PNAS 85: 2568-2572 (Apr. 1988).
Samuel et al, "Comparison of the Glycoliped Receptor . . . " Inf. Immun. 58: 611-618 (Mar. 1990).
Ito et al, "Cloning and nucleotide sequencing of Vero toxin 2 . . . " Microb. Pathog. 8: 47-60 (1990).
Jackson et al., "Mutational Analysis of the Shiga Toxin . . . ", J. Bacter. 172(6): 3346-3350, Jun. 1990.
Yamasaki et al., "Importance of arginine at position 170 . . .", Microb. Pathog. 11(1): 1-9, Jul. 1991, abstract only.
Gyles et al., "Cloning and nucleotide sequence analysis . . .", Microb. Pathog. 5(6): 419-26, 1988, abstracted in Chem. Abst. 110: 181, Abst. #186883h, Feb. 22, 1989.
Frankel et al., Mol. Cell. Biol. 9(2): 415-420, Feb. 1989.
Schulz et al., Principle of Protein Structure, pp. 14-16, 1979.
Schlossman et al., Molecular and Cellular Biology, 9(11):5012-5021 (1989).
MacLeod et al., Veterinary Microbiology, vol. 29:309-318 (1991).
Gordon et al, "An Enzymatic Mutant of Shiga-like Toxin II Variant is a Vaccine Candidate for Edema Disease of Swine," Abstracts Twenty-Seventh Joint Conference on Cholera and Related Diarrheal Diseases, 149-152 (1991) .

Affiliated with

Also associated with

Rating

Immunogenic shiga-like toxin II variant mutants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic shiga-like toxin II variant mutants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic shiga-like toxin II variant mutants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1948411